

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

8 September 2017 (08.09.2017)



WIPO | PCT



(10) International Publication Number

WO 2017/149109 A1

(51) International Patent Classification:

A61K 38/26 (2006.01) *A61P 17/02* (2006.01)

A61P 3/10 (2006.01)

(21) International Application Number:

PCT/EP2017/054986

(22) International Filing Date:

3 March 2017 (03.03.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16158737.3 4 March 2016 (04.03.2016) EP

16173916.4 10 June 2016 (10.06.2016) EP

(71) Applicant: **NOVO NORDISK A/S** [DK/DK]; Novo Allé,
2880 Bagsværd (DK).

(72) Inventor: **RASMUSSEN, Søren**; Novo Allé, 2880 Bags-
værd (DK).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: LIRAGLUTIDE IN DIABETIC FOOT ULCER

(57) Abstract: The present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.



WO 2017/149109 A1

LIRAGLUTIDE IN DIABETIC FOOT ULCER

The present invention relates to the GLP-1 receptor agonist liraglutide for use in diabetic foot ulcer conditions.

BACKGROUND

5 Diabetes is a metabolic disorder characterized by hyperglycaemia that is associated with a high risk of cardiovascular and other serious health-related consequences. A person with diabetes is two to three times more likely to die from cardiovascular causes than people with no history of diabetes, even after controlling for other cardiovascular risk factors. They are also at very high risk of developing serious
10 microvascular complications ultimately leading to premature death: nephropathy and renal failure, retinal disease and blindness, autonomic and peripheral neuropathy, as well as other conditions related to the vascular system: hypertension, lower limb amputation, cognitive decline, and erectile dysfunction.

The majority of people with diabetes have type 2 diabetes, which is
15 characterised by insulin resistance and eventually impaired insulin secretion. Optimal glycaemic control is the treatment goal in subjects with type 2 diabetes, since the risk of long-term complications is increased with poor glycaemic control. Despite the availability of several oral anti-diabetic drugs and insulin, a significant proportion of subjects with type 2 diabetes do not achieve the recommended target levels. With the increasing
20 incidence and prevalence of type 2 diabetes, there is an unmet medical need for treatment alternatives with improved efficacy, safety, and convenience.

SUMMARY

In some embodiments the present invention relates to a method of treating type 2 diabetes, comprising administering liraglutide in a therapeutically effective amount to a
25 subject in need thereof, wherein said subject has (i) vascular disease selected from the group consisting of cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and chronic heart failure, and/or (ii) one or more risk factors of vascular disease selected from the group consisting of microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic
30 dysfunction, left ventricular diastolic dysfunction, and ankle/brachial index <0.9 ; wherein said method reduces or delays diabetic foot ulcer.

DESCRIPTION

Diabetic foot ulcer is a late stage complication of diabetes and is the primary reason for hospitalisation among late stage diabetic indications. Diabetic foot ulcers are also a major reason for diabetes-related amputations.

5 In some embodiments the present invention relates to a method for reducing or delaying the development of diabetic foot ulcer, comprising administering liraglutide in a therapeutically effective amount to a subject in need thereof, wherein the subject has type 2 diabetes and one or more risk factors of vascular disease.

10 In some embodiments the present invention relates to a method of treating type 2 diabetes, comprising administering liraglutide in a therapeutically effective amount to a subject in need thereof, wherein said subject has (i) vascular disease selected from the group consisting of cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and chronic heart failure, and/or (ii) one or more risk factors of vascular disease selected from the group consisting of microalbuminuria, 15 proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction, and ankle/brachial index <0.9 ; wherein said method reduces or delays diabetic foot ulcer.

20 In some embodiments the present invention relates to a method of treating type 2 diabetes, comprising administering liraglutide in a therapeutically effective amount to a subject in need thereof, wherein said subject has (i) vascular disease selected from the group consisting of cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and chronic heart failure, and/or (ii) one or more risk factors of vascular disease selected from the group consisting of microalbuminuria, 25 proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction, and ankle/brachial index <0.9 ; wherein said method a) reduces or delays diabetic foot ulcer; b) reduces or delays serious diabetic foot ulcer; c) reduces or delays severe or moderate diabetic foot ulcer; and/or d) reduces or delays severe diabetic foot ulcer.

30 In some embodiments the method reduces or delays severe or moderate diabetic foot ulcer. In some embodiments the method reduces or delays severe diabetic foot ulcer. In some embodiments severity of a diabetic foot ulcer may be classified as severe (ulcer penetrating to bone or joint), moderate (ulcer penetrating through tendon or capsule), or mild (superficial ulcer not penetrating tendon, bone, or joint). In some 35 embodiments a severe diabetic foot ulcer is present when the diabetic foot ulcer results in considerable interference with the subject's daily activities, and is unacceptable. In some embodiments a moderate diabetic foot ulcer is present when the diabetic foot ulcer

results in marked symptoms, moderate interference with the subject's daily activities. In some embodiments a mild diabetic foot ulcer is present when the diabetic foot ulcer results in no or transient symptoms, no interference with the subject's daily activities.

In some embodiments the method reduces or delays serious diabetic foot ulcer.

- 5 In some embodiments degree of a diabetic foot ulcer may be classified as either serious or non-serious, for example depending on its surface area, depth and location. In some embodiments a serious diabetic foot ulcer is a foot ulcer which results in the subject experiencing at least one event selected from the group consisting of (i) death; (ii) a life-threatening experience; (iii) hospitalisation or prolongation of existing hospitalisation;
- 10 (iv) a persistent or significant disability/incapacity; (v) important medical events that may not result in death, be life-threatening, or require hospitalisation when, based upon appropriate medical judgement, they may jeopardise the subject and may require medical or surgical intervention to prevent one of the outcomes (i)-(iv) listed in this definition. In some embodiments suspicion of transmission of infectious agents is also a
- 15 serious diabetic foot ulcer. A non-serious diabetic foot ulcer is a diabetic foot ulcer which does not fulfil the definition of a serious diabetic foot ulcer. In some embodiments the term "life-threatening" as used herein refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it was more severe. In some embodiments a subject is
- 20 considered to be hospitalised (i) when admitted to a hospital (irrespective of the duration of physical stay), or (ii) when not admitted to a hospital, but stays at the hospital for treatment or observation for more than 24 hours. In some embodiments a subject is not considered to be hospitalised when hospitalised for (i) administrative, trial related and social purposes, or (ii) surgical procedures planned prior to starting administration of
- 25 liraglutide. In some embodiments the term "disability/incapacity" as used herein means that following the event the subject or clinical investigation subject has significant, persistent or permanent change, impairment, damage or disruption in his body function or structure, physical activity and/or quality of life. In some embodiments the term "important medical events" as used herein means events which may jeopardise the
- 30 subject or require intervention to prevent a seriousness criterion, for example adverse events which suggest a significant hazard or puts the subject or clinical investigation subject at risk, such as drug-interactions, contra-indications or precautions, occurrence of malignancies or development of drug dependency or drug abuse. In some
- 35 embodiments a serious diabetic foot ulcer is a foot ulcer which results in death of the subject, also referred to herein as fatal outcome. In some embodiments a serious diabetic foot ulcer is a foot ulcer which results in the subject experiencing a life-

threatening experience. In some embodiments a serious diabetic foot ulcer is a foot ulcer which results in the subject experiencing hospitalisation or prolongation of existing hospitalisation. In some embodiments a serious diabetic foot ulcer is a foot ulcer which results in the subject experiencing a persistent or significant disability/incapacity. The terms "subject" and "patient" may be used interchangeably herein.

In some embodiments the method further reduces or delays a fatal outcome for said subject.

In some embodiments the method further reduces or delays recovery with sequelae. In some embodiments the outcome of a diabetic foot ulcer may be classified as fatal, not recovered, recovered with sequelae, recovering, or recovered. The term "recovered with sequelae" may refer to the subject having recuperated but retained one or more pathological conditions resulting from the diabetic foot ulcer, for example an amputation. In some embodiments the term "recovered with sequelae" refers to the patient having recovered from the diabetic foot ulcer, but with a lasting effect due to a disease, injury, treatment or procedure caused by the diabetic foot ulcer.

In some embodiments the method comprises at least 16 months of chronic administration of liraglutide. In some embodiments the method comprises at least 14 months of chronic administration of liraglutide. In some embodiments the method comprises at least 20 months of chronic administration of liraglutide.

In some embodiments "reduces or delays" when used herein with reference to the method of the invention is "reduces the risk of".

Subject and subpopulations

The subject to be administered liraglutide according to the present invention may be human, such as an adult human.

The subject to receive liraglutide administration according to the methods of the present invention has type 2 diabetes and has (i) vascular disease selected from the group consisting of cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, or chronic heart failure, and/or (ii) one or more risk factors of vascular disease. In some embodiments the subject has type 2 diabetes and cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, or chronic heart failure. The subject may have type 2 diabetes and cardiovascular disease. The subject may have type 2 diabetes and cerebrovascular disease. The subject may have type 2 diabetes and peripheral vascular disease. The subject may have type 2 diabetes and chronic renal failure. The subject may have type 2 diabetes and chronic heart failure. In some embodiments the subject has type 2 diabetes

and one or more risk factors of vascular disease. These vascular diseases may be referred to as concomitant, i.e. one or more vascular diseases are present in the subject at the same time as type 2 diabetes.

5 In some embodiments the subject is at least 50 years of age, such as at least 60 years of age.

In some embodiments the subject has HbA_{1c} of at least 7.0%, e.g. prior to receiving liraglutide administration.

10 In some embodiments the subject is, except for liraglutide, anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s). The subject may be anti-diabetic drug naive. The subject may be treated with one or more oral anti-diabetic drugs (OADs). The subject may be treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s). In some embodiments the OAD may be selected from the group consisting of sulfonylureas, insulin secretagogues, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and combinations thereof. In some embodiments the OAD is sulfonylurea (e.g. glimepiride, glipizide, glyburide). In some embodiments the OAD is insulin secretagogues (e.g. biguanides such as metformin or meglitinides such as nateglinide). In some 20 embodiments the OAD is thiazolidinediones (e.g. pioglitazone, rosiglitazone). In some embodiments the OAD is alpha-glucosidase inhibitors (e.g. acarbose, miglitol, voglibose). In some embodiments the OAD is sodium-glucose co-transporter-2 inhibitors (e.g. dapagliflozin, canagliflozin, empagliflozin). In some embodiments the OAD is dipeptidyl peptidase-4 inhibitors (e.g. sitagliptin). In some embodiments the OAD is not a 25 dipeptidyl peptidase-4 inhibitor.

In some embodiments the subject (i) is at least 50 years of age and has cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, or chronic heart failure, or (ii) is at least 60 years of age and has one or more risk factors of vascular disease.

30 In some embodiments the subject a) (i) is at least 50 years of age and has vascular disease selected from the group consisting of cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, or chronic heart failure, or (ii) is at least 60 years of age and has risk factors of vascular disease; b) has HbA_{1c} of at least 7.0%, e.g. at the time prior to receiving liraglutide administration; 35 and c) is anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs

(OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s).

The cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and/or chronic heart failure may be selected from the group consisting of: a) prior myocardial infarction; b) prior stroke or prior transient ischaemic attack (TIA); c) prior coronary, carotid or peripheral arterial revascularisation; d) >50% stenosis on angiography or other imaging of coronary, carotid or lower extremity arteries; e) history of symptomatic coronary heart disease documented by positive exercise stress test or any cardiac imaging, or unstable angina pectoris with ECG (electrocardiogram) changes; f) asymptomatic cardiac ischemia documented by positive nuclear imaging test or exercise test or dobutamine stress echo; g) chronic heart failure NYHA class II-III; and h) chronic renal failure, having clinically reached a stage corresponding to a glomerular filtration rate < 60 mL/min/1.73m² per Modification of Diet in Renal Disease (MDRD) or < 60 mL/min per Cockcroft-Gault formula. In some embodiments, the subject experienced the a) myocardial infarction; b) stroke or transient ischaemic attack (TIA); or c) coronary, carotid or peripheral arterial revascularisation as a prior event before the time of liraglutide administration.

The glomerular filtration rate per MDRD may be as defined in formula Ia: $GFR (mL/min/1.73 m^2) = 175 \times (S_{cr})^{-1.154} \times (Age)^{-0.203} \times (0.742 \text{ if female}) \times (1.212 \text{ if African American})$ [Ib].

The "Cockcroft-Gault formula" may be as defined by Formula Ib: $CrCl (mL/min) = (N \times [140 - age (years)] \times weight^* (kg)) / Serum \ creatinine (\mu M)$ [Ib], wherein CrCl is the Cockcroft and Gault creatinine clearance, wherein N is 1.23 for males and 1.04 for females, and wherein if actual weight is greater than 120% IBW then weight is the ideal body weight (IBW) as defined in Formula II: $IBW (kg) = (no \ of \ inches \ over \ 5ft \times 2.3) + M$ [II], wherein M is 50 for males and 45.5 for females.

Heart failure exists in different degrees of severity. The most commonly used classification system of heart failure is the New York Heart Association Functional Classification (also referred to as "NYHA"). NYHA categorises subjects in one of four classes I-IV (Table A), based on their degree of limitation during physical activity, and optionally an additional subgroup A-D based on objective assessments, for further details see The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256).

35

Table A. NYHA class I-IV criteria

NYHA Class	Functional Capacity of the subject
I	Subjects with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.
II	Subjects with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
III	Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
IV	Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.

The cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and/or chronic heart failure may be myocardial infarction. The cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and/or chronic heart failure may be stroke or prior transient ischaemic attack (TIA). The cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and/or chronic heart failure may be coronary, carotid or peripheral arterial revascularisation. The cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and/or chronic heart failure may be >50% stenosis on angiography or other imaging of coronary, carotid or lower extremity arteries. The cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and/or chronic heart failure may be history of symptomatic coronary heart disease documented by positive exercise stress test or any cardiac imaging, or unstable angina pectoris with ECG changes. The cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and/or chronic heart failure may be asymptomatic cardiac ischemia documented by positive nuclear imaging test or exercise test or dobutamine stress echo. The cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and/or chronic heart failure may be chronic heart failure NYHA class II-III. The cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and/or chronic heart failure may be chronic renal failure, having clinically reached a stage corresponding

to a glomerular filtration rate $< 60 \text{ mL/min/1.73m}^2$ per Modification of Diet in Renal Disease (MDRD) or $< 60 \text{ mL/min}$ per Cockcroft-Gault formula.

The "risk factors of vascular disease" (also referred to herein as "other specified risk factors of vascular disease") may be selected from the group consisting of
5 microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction, and ankle/brachial index < 0.9 . In some embodiments the "risk factors of vascular disease" may be selected from the group consisting of a) microalbuminuria or proteinuria; b) hypertension and/or left
10 ventricular hypertrophy by ECG or imaging; c) left ventricular systolic or diastolic dysfunction by imaging; and d) ankle/brachial index < 0.9 . The "risk factors of vascular disease" may be microalbuminuria or proteinuria. The "risk factors of vascular disease" may be hypertension and/or left ventricular hypertrophy by ECG or imaging. The "risk factors of vascular disease" may be left ventricular systolic or diastolic dysfunction by imaging. The "risk factors of vascular disease" may be ankle/brachial index < 0.9 .

15

BMI

In some embodiments the subject has a BMI of at least 30 kg/m^2 . BMI (body mass index) is a measure of body fat based on height and weight. The formula for calculation is $\text{BMI} = (\text{weight in kilograms})/(\text{height in meters})^2$. In some embodiments the
20 subject has a BMI in the range of $30\text{-}50 \text{ kg/m}^2$. In some embodiments the subject has a BMI of at least 33 kg/m^2 . In some embodiments the subject has a BMI of at least 35 kg/m^2 . In some embodiments the subject has a BMI of at least 37 kg/m^2 . In some embodiments the subject has a BMI of at least 40 kg/m^2 . In some embodiments the subject has a BMI of up to 45 kg/m^2 . In some embodiments the subject has a BMI of up
25 to 40 kg/m^2 .

Exclusion criteria

In some embodiments the subject does not have type 1 diabetes. In some
30 embodiments the subject does not receive administration of a GLP-1 receptor agonist (exenatide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor prior to initiating administration of liraglutide according to the present invention. In some
embodiments the subject does not receive administration of insulin other than insulin selected from the group consisting of human neutral protamine hagedorn (NPH) insulin, long-acting insulin analogue or premixed insulin. In some embodiments, and in
35 connection with intercurrent illness, the subject receives short-term administration of insulin other than insulin selected from the group consisting of human NPH insulin, long-

acting insulin analogue or premixed insulin. Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (e.g., diabetic ketoacidosis) in the previous 3 months. In some embodiments the subject does not have an acute coronary or cerebrovascular event in the previous 14 days. In some embodiments the subject does not receive continuous renal replacement therapy. In some embodiments the subject does not have end-stage liver disease. In some embodiments the subject does not have chronic heart failure NYHA IV. In some embodiments the subject does not have a prior solid organ transplant or awaiting solid organ transplant. In some embodiments the subject does not have family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC). In some embodiments the subject does not have personal history of non-familial medullary thyroid carcinoma. In some embodiments the subject does not have malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years. In some embodiments the subject has intraepithelial squamous cell carcinoma of the skin (Bowen's disease) treated with topical 5-fluorouracil (5FU) and subjects with basal cell skin cancer.

Liraglutide

Liraglutide is the GLP-1 receptor agonist Arg34,Lys26-(N-epsilon-(gamma-L-glutamyl(N-alfa-hexadecanoyl)))-GLP-1(7-37). Liraglutide may be prepared as described in Example 37 of WO98/08871.

Pharmaceutical composition

Liraglutide may be administered in the form of a pharmaceutical composition. The pharmaceutical composition may comprise liraglutide in a concentration from 0.1 mg/ml to 100 mg/ml. In some embodiments the pharmaceutical composition comprises 0.01-50 mg, or 0.01-20 mg, or 0.01-10 mg/ml liraglutide. In some embodiments the pharmaceutical composition comprises 1-20 mg/ml liraglutide.

The pharmaceutical composition may further comprise one or more pharmaceutically acceptable excipients, for example selected from the group consisting of buffer system, preservative, tonicity agent, chelating agent, stabilizer and surfactant. In some embodiments the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients, such as one or more selected from the group consisting of a buffer, an isotonic agent, and a preservative. The formulation of pharmaceutically active ingredients with various excipients is known in the art, see e.g. Remington: The Science and Practice of Pharmacy (e.g. 19th edition (1995), and any

later editions). The term "excipient" broadly refers to any component other than the active therapeutic ingredient(s), e.g. liraglutide. The excipient may be an inert substance, an inactive substance, and/or a not medicinally active substance.

5 In some embodiments the pharmaceutical composition comprises a phosphate buffer, such as a sodium phosphate buffer, e.g. disodium phosphate. In some embodiments the pharmaceutical composition comprises an isotonic agent, such as propylene glycol. In some embodiments the pharmaceutical composition comprises a preservative, such as phenol.

10 The pharmaceutical composition may be in the form of a solution or a suspension. In some embodiments the pharmaceutical composition is aqueous composition, such as an aqueous solution or an aqueous suspension. The term "aqueous composition" is defined as a composition comprising at least 50 %w/w water. Likewise, the term "aqueous solution" is defined as a solution comprising at least 50 %w/w water, and the term "aqueous suspension" is defined as a suspension comprising at least 50
15 %w/w water. An aqueous composition may comprise at least 50% w/w water, or at least 60%, 70%, 80%, or even at least 90% w/w of water. In some embodiments the pharmaceutical composition has a pH in the range of 7.5-9.0.

In some embodiments liraglutide is administered in the form of a pharmaceutical composition comprising about 1-20 mg/ml liraglutide, about 2-15 mM phosphate buffer,
20 about 2-25 mg/ml propylene glycol, about 1-18 mg/ml phenol, and has a pH in the range of 7.5-9.0. In some embodiments liraglutide is administered in the form of a pharmaceutical composition comprising about 6 mg/ml liraglutide, about 1.42 mg/ml disodium phosphate dihydrate, about 14.0 mg/ml propylene glycol, about 5.5 mg/ml phenol, and has pH of about 8.15. In some embodiments liraglutide is administered in
25 the form of a pharmaceutical composition comprising 6 mg/ml liraglutide, 1.42 mg/ml disodium phosphate dihydrate, 14.0 mg/ml propylene glycol, 5.5 mg/ml phenol, and has pH of 8.15.

Administration regimen

Liraglutide may be administered in a therapeutically effective amount, such as
30 an amount therapeutically effective to treat type 2 diabetes. The therapeutically effective amount of liraglutide can be assessed by a medical doctor. The dosage of liraglutide may be in the range from 0.1 to 10 mg.

Liraglutide may be administered once daily. In some embodiments liraglutide is administered once daily at any time in the day. In some embodiments the daily dosage
35 of liraglutide is in the range from 0.4 to 4.0 mg, such as in the range from 0.4 to 2.0 mg.

In some embodiments the daily dosage of liraglutide is selected from the group consisting of 0.6, 1.2, and 1.8 mg. In some embodiments the daily dosage of liraglutide is 3.0 mg.

5 In some embodiments the term "chronic treatment" as used herein with reference to liraglutide means administration in an amount and frequency to provide a therapeutic effect. In some embodiments the term "chronic treatment" as used herein with reference to liraglutide means once daily administration 0.4-4.0 mg, such as 0.6, 1.2, or 1.8 mg, liraglutide.

10 Liraglutide may be administered via parenteral administration, for example subcutaneous injection. Liraglutide may be administered using a pen-injector, such as a 3 ml disposable pen-injector.

Unless otherwise states, ranges herein include their end points. In some embodiments the term "a" means "one or more". In some embodiments, and unless 15 otherwise indicated in the specification, terms presented in singular form also include the plural situation. Herein the term "about" means $\pm 10\%$ of the value referred to, and includes the value.

EXAMPLES

List of Abbreviations

20 MACE: Major adverse cardiovascular event
HbA_{1c}: Glycosylated haemoglobin
GLP-1: Glucagon-like peptide-1
BMI: Body mass index
CV: cardiovascular
25 OAD: Oral antidiabetic drug
TIA: transient ischaemic attack
CI: Confidence interval

TRIAL: Materials and Methods

30 A long-term, multi-centre, international, randomised double-blind, placebo-controlled trial with 9340 human subjects was carried out with treatment for at least 3.5 years and up to 5 years per subject; and this trial concerned the incidence of cardiovascular events in adult human subjects with type 2 diabetes that were at high risk for cardiovascular events, including such subjects with existing cardiovascular disease.
35 The primary objective of this trial was to determine the long term effect of treatment

with liraglutide compared to placebo on cardiovascular events in subjects with type 2 diabetes. The secondary objective was to assess the efficacy and safety with regard to clinically important events or other surrogate parameters of treatment with liraglutide compared to placebo in adults with type 2 diabetes that were at high risk for cardiovascular events. All trial endpoints were collected and assessed throughout the entire duration of the trial. Subject inclusion and exclusion criteria were as described in Table 2. The subject's characteristics, cardiovascular risk profile, renal function, cardiovascular medication, and antidiabetic treatment regimens of the randomised subjects at baseline were as shown in Tables 3a-e. Overall trial duration was planned as 18 months of recruitment period followed by 42 months of treatment from last subject randomised. The trial started with an open-label run-in period of two weeks with placebo following which subjects were randomised in a 1:1 manner to receive liraglutide or placebo as an add-on to their standard of care (SOC) treatment. The subject's SOC treatment was as shown in Table 4. After randomisation, treatment with liraglutide or placebo was double-blind throughout the trial. Subjects were started on 0.6 mg of liraglutide or placebo. The term "placebo" as used herein refers to a formulation identical to the liraglutide formulation except not comprising liraglutide and the placebo was administered in the volume used in the equivalent liraglutide dosage. Dose escalation of liraglutide or placebo proceeded to 1.2 mg after one week followed by dose escalation to 1.8 mg after one week. After the dose escalation, 95% of subjects received 1.8 mg of liraglutide or placebo, 5% of subjects received 1.2 mg of liraglutide or placebo, and 5% of subjects received 0.6 mg of liraglutide or placebo. Dose increase period could be extended if required in view of a subject's tolerance to the trial product (i.e. liraglutide or placebo). The dosage could be reduced at any time in the trial if required by the subject's tolerance to the trial product. Subjects received liraglutide or placebo by subcutaneous administrations once daily in addition to the subject's standard treatment at a maximum dose of 1.8 mg liraglutide or placebo. The subcutaneous injection was made either in the abdomen, thigh or upper arm. The formulations were administered in the form of an aqueous solution comprising liraglutide or placebo, both using a 3 ml disposable pen-injector. This pen-injector was identical for the liraglutide and placebo administrations. This aqueous solution contained 6.0 mg/ml liraglutide, 1.42 mg/ml disodium phosphate dihydrate, 14.0 mg/ml propylene glycol, 5.5 mg/ml phenol, and had pH 8.15. Liraglutide may be prepared as described in WO98/08871.

The term "baseline" herein (e.g. used as part of "baseline characteristics" or "baseline cardiovascular risk profile") may refer to the level of a certain parameter (e.g. level of HbA1c) by the determination made in connection with the medical visit at the

time of randomisation of the subject. In some embodiments the term baseline refers to a parameter before initiating administration of liraglutide, e.g. the history of a certain event in a subject.

The results of this trial may be presented herein as a number or fraction of subjects experiencing an event. Alternatively, the results of this trial may be presented with hazard ratios estimated in a Cox proportional hazard model, which is the standard statistical model used for estimating time to an event. The term "hazard ratio" (also referred to as "HR") as used herein means the instantaneous risk ratio of experiencing an event when administered liraglutide compared to placebo which are the two treatments in this trial. An upper limit of the 95% confidence interval (CI) for the HR of less than 1.00 means that the estimated treatment ratio between liraglutide and placebo with respect to the event of interests is statistically significant in favour of liraglutide on a 5% significance level. A 5% significance level is the standard level for investigating significance in clinical trials. For example, a HR value of 0.78 for time to first CV death with a 95% CI of (0.66 ; 0.94) means that liraglutide provides an estimated 22% risk reduction of experiencing CV death at any given point in time compared to placebo and this risk reduction is statistically significant because 0.94 is less than 1.00.

Table 2. Subject inclusion and exclusion criteria (all inclusion criteria were fulfilled for eligible subjects; one or more exclusion criteria were fulfilled for subjects to be excluded; however, 150 patients violated at least one inclusion or exclusion criteria)

Inclusion Criteria	Exclusion Criteria
- Men or women with type 2 diabetes - Age $\geq$ 50 years at screening and concomitant cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, or chronic heart failure selected from the group consisting of: a) prior myocardial infarction; b) prior stroke or prior transient ischaemic attack (TIA); c) prior coronary, carotid or peripheral arterial revascularisation; d) >50% stenosis on angiography or other imaging of coronary, carotid or lower extremity arteries; e) history of symptomatic	- Type 1 diabetes - Use of a GLP-1 receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulin other than human neutral protamine hagedorn (NPH) insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Short-term use of other insulin during this period in connection with intercurrent illness

coronary heart disease documented by positive exercise stress test or any cardiac imaging, or unstable angina pectoris with ECG (electrocardiogram) changes; f) asymptomatic cardiac ischemia documented by positive nuclear imaging test or exercise test or dobutamine stress echo; g) chronic heart failure NYHA class II-III; and h) chronic renal failure, having clinically reached a stage corresponding to a glomerular filtration rate < 60 mL/min/1.73m² per Modification of Diet in Renal Disease (MDRD) or < 60 mL/min per Cockcroft-Gault formula; ; wherein "prior" refers to before initiation of liraglutide administration; OR age ≥ 60 years at screening and other specified risk factors of vascular disease selected from the group consisting of: a) microalbuminuria or proteinuria; b) hypertension and/or left ventricular hypertrophy by ECG or imaging; c) left ventricular systolic or diastolic dysfunction by imaging; and d) ankle/brachial index <0.9 • HbA_{1c} ≥ 7.0% at screening • Anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s)	was allowed, at Investigator's discretion • Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (e.g., diabetic ketoacidosis) in the previous 3 months • An acute coronary or cerebrovascular event in the previous 14 days • Current continuous renal replacement therapy • End-stage liver disease • Chronic heart failure NYHA IV • A prior solid organ transplant or awaiting solid organ transplant • Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC) • Personal history of non-familial medullary thyroid carcinoma • Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years. Subjects with intraepithelial squamous cell carcinoma of the skin (Bowen's disease) treated with topical 5-fluorouracil (5FU) and subjects with basal cell skin cancer are allowed to enter the trial
--	---

Table 3a. Baseline characteristics

	Liraglutide	Placebo
Number of subjects	4668	4672
Male sex, N (%)	3011 (64.5)	2992 (64.0)
Age, years	64.2	64.4
Diabetes duration, years	12.8	12.9
HbA _{1c} , %	8.7	8.7
BMI, kg/m ²	32.5	32.5
Body weight, kg	91.9	91.6
Systolic blood pressure, mmHg	135.9	135.9
Diastolic blood pressure, mmHg	77.2	77.0
Heart failure*, N (%)	832 (17.8)	821 (17.6)

Full analysis set; data are mean unless stated otherwise. *: Heart failure includes NYHA class I, II and III. %: proportion of subjects. BMI: body mass index. HbA_{1c}: glycosylated haemoglobin. NYHA: New York Heart Association.

Table 3b. Cardiovascular risk profile at baseline

	Liraglutide		Placebo	
	N	%	N	%
Number of subjects	4668		4672	
Age ≥50 years and established CV disease	3815	81.7	3749	80.2
Prior myocardial infarction	1464	31.4	1400	30.0
Prior stroke or prior TIA	730	15.6	777	16.6
Prior arterial revascularisation	1766	37.8	1719	36.8
>50% stenosis on angiography	1188	25.4	1191	25.5
Documented history of symptomatic coronary heart disease	412	8.8	406	8.7
Documented asymptomatic cardiac ischaemia	1241	26.6	1231	26.3
Chronic heart failure NYHA II or III	653	14.0	652	14.0
Chronic kidney failure	1185	25.4	1122	24.0
Age ≥60 years and risk factors for CV	853	18.3	923	19.8

disease				
Microalbuminuria or proteinuria	504	10.8	560	12.0
Hypertension and/or left ventricular hypertrophy	249	5.3	253	5.4
Left ventricular systolic or diastolic dysfunction	204	4.4	191	4.1
Ankle/brachial index <0.9	126	2.7	134	2.9

Full analysis set. *Chronic kidney failure was defined as having clinically reached a stage corresponding to eGFR <60 mL/min/1.73m² per MDRD or <60 mL/min per Cockcroft-Gault formula, reported at the discretion of the investigator. %: proportion of subjects. CV: cardiovascular. eGFR: estimated glomerular filtration rate. MDRD: modification of diet in renal disease. N: number of subjects. NYHA: New York Heart Association. TIA: transient ischaemic attack.

Table 3c. Renal function at baseline

	Liraglutide		Placebo	
	N	%	N	%
Number of subjects	4668	100.0	4672	100.0
Normal renal function (eGFR ≥90)	1620	34.7	1655	35.4
Mild impairment (eGFR 60–89)	1932	41.4	1975	42.3
Moderate impairment (eGFR 30–59)	999	21.4	935	20.0
Severe impairment (eGFR <30)	117	2.5	107	2.3

Full analysis set. eGFR (mL/min/1.73 m²) as per MDRD formula. %: proportion of subjects. eGFR: estimated glomerular filtration rate; MDRD: modification of diet in renal disease. N: number of subjects.

5

Table 3d. Cardiovascular medication at baseline

	Liraglutide		Placebo	
	N	%	N	%
Number of subjects	4668		4672	

Antihypertensive therapy	4322	92.6	4299	92.0
Beta blockers	2649	56.7	2524	54.0
Calcium channel blockers	1531	32.8	1477	31.6
ACE inhibitors and ARB	3898	83.5	3833	82.0
Others	468	10.0	452	9.7
Diuretics	1950	41.8	1949	41.7
Loop diuretics	823	17.6	833	17.8
Others	1405	30.1	1392	29.8
Lipid-lowering drugs	3554	76.1	3511	75.1
Statins	3395	72.7	3334	71.4
Others	655	14.0	676	14.5
Platelet aggregation inhibitors	3203	68.6	3119	66.8
Acetylsalicylic acid	2975	63.7	2899	62.1
Others	718	15.4	743	15.9
Other anti-thrombotic medication	309	6.6	314	6.7

Full analysis set. 83 subjects had missing initiation drug date, these were assumed to be on treatment at baseline. %: proportion of subjects. ACE: angiotensin converting enzyme. ARB: angiotensin receptor blocker. N: number of subjects.

Table 3e. Antidiabetic treatment regimens at baseline

	Liraglutide		Placebo	
	N	%	N	%
Number of subjects	4668		4672	
Insulin-naïve	2633	56.4	2548	54.5
Not on treatment*	196	4.2	170	3.6
OADs only	2437	52.2	2378	50.9
Insulin treatment	2035	43.6	2124	45.5
Insulin only	361	7.7	376	8.0
Insulin + OADs	1674	35.9	1748	37.4

Full analysis set. *: Includes subjects not on insulin/OAD and subjects on no pharmacologic treatment. %: proportion of subjects. N: number of subjects. OAD: oral antidiabetic drug.

Table 4. Standard of care guidelines for subjects in this trial

Parameter	Standard of care guideline
Blood glucose	HbA1c $\leq 7.0\%$ (individualized depending on patient). If $>7.0\%$, additional HbA1c measurement after 3 m. If HbA1c still $>7.0\%$, treatment was intensified to achieve target if appropriate.
Therapy	Lifestyle modifications and metformin are considered foundational therapy in most countries of this trial
Intensification	Add-on therapy: thiazolidinediones, sulfonylureas, α -glucosidase inhibitors, according to local labels (dipeptidyl peptidase-4 inhibitors and other incretin based therapies were not allowed). Insulin therapy should be based on local practice, including basal, basal/bolus, premix, and mealtime bolus (SIT).
Blood pressure	Target: 130/80 mm Hg.
Antihypertensive therapy	First line: ACE inhibitors or ARBs. Based on individual patient needs: Ca^{2+} -blockers, diuretics, others.
Lipid targets and therapy	LDL <100 mg/dL (<70 mg/dL in patients with previous cardiovascular events). Statins recommended for all patients. Second line therapy at investigator discretion.
Antiplatelet therapy	Aspirin or clopidogrel (if aspirin intolerant) for patients with prior cardiovascular events (MI, cerebrovascular accident, or revascularization).

Example 1: Diabetic foot ulcer

Results from this trial concerning diabetic foot ulcer are shown in Table 4.

5

Table 4. Diabetic foot ulcer events and characterisation thereof

	Liraglutide				Placebo			
	N	%	E	R	N	%	E	R
Total number of subjects	4668				4672			
PYO in trial	17819				17736			
Diabetic foot ulcer events	181	3.9	268	1.50	198	4.2	304	1.71
<i>Serious</i>								
Yes	93	2.0	141	0.79	116	2.5	146	0.82
No	102	2.2	127	0.71	103	2.2	158	0.89
<i>Severity</i>								

Severe	50	1.1	68	0.38	64	1.4	74	0.42
Moderate	97	2.1	125	0.70	107	2.3	143	0.81
Mild	57	1.2	75	0.42	60	1.3	87	0.49
<i>Outcome</i>								
Fatal	2	<0.1	2	0.01	5	0.1	5	0.03
Not recovered	32	0.7	35	0.20	36	0.8	39	0.22
Recovered with sequelae	30	0.6	40	0.22	48	1.0	60	0.34
Recovering	8	0.2	10	0.06	6	0.1	6	0.03
Recovered	134	2.9	180	1.01	131	2.8	193	1.09
Unknown	1	<0.1	1	<0.01	1	<0.1	1	<0.01

?: proportion of subjects. E: number of events. MESI: medical event of special interest.

N: number of subjects. PYO: patient years of observation. R: event rate per 100 observation years.

These results show that liraglutide reduced the frequency of diabetic foot ulcer compared to placebo. Compared to placebo liraglutide reduced the frequency of (i) serious diabetic foot ulcer as well as (ii) severe or moderate diabetic foot ulcer. Reduced frequency of outcomes which were either fatal or resulted in recovery with sequelae was shown with

5 liraglutide compared to placebo.

Table 5. Adverse events by preferred term with frequency of at least 0.1%

	Liraglutide		Placebo	
Preferred term	%	R	%	R
Diabetic foot	2.8	1.0	3.3	1.3
Skin ulcer	0.6	0.2	0.6	0.2
Diabetic foot infection	0.3	<0.1	0.3	<0.1
Gangrene	0.2	<0.1	0.3	<0.1

Full analysis set. ?: proportion of subjects experiencing at least one event. AE: adverse event. MESI: medical event of special interest. PT: preferred term. R: rate (events per 100 PYO). SAE: serious adverse event. PYO: patient years of observation.

Diabetic foot ulcer events observed over time in a Kaplan-Meier plot showed that chronic administration of liraglutide for at least 16 months reduced the risk of developing diabetic foot ulcer compared to placebo.

5

While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true
10 spirit of the invention.

CLAIMS

1. A method for reducing or delaying the development of diabetic foot ulcer, comprising administering liraglutide in a therapeutically effective amount to a subject in need thereof, wherein the subject has type 2 diabetes and one or more risk factors of
5 vascular disease.
2. A method of treating type 2 diabetes, comprising administering liraglutide in a therapeutically effective amount to a subject in need thereof, wherein said subject has
10 (i) one or more vascular diseases selected from the group consisting of cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and chronic heart failure, and/or
 (i) one or more risk factors of vascular disease selected from the group consisting of microalbuminuria, proteinuria, hypertension, left ventricular
15 hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction, and ankle/brachial index <0.9;

 wherein said method reduces or delays diabetic foot ulcer.
- 20 3. The method according to any one of the preceding claims, wherein said method reduces or delays severe or moderate diabetic foot ulcer.
4. The method according to any one of the preceding claims, wherein said method reduces or delays severe diabetic foot ulcer.
- 25 5. The method according to any one of the preceding claims, wherein said method reduces or delays serious diabetic foot ulcer.
6. The method according to any one of the preceding claims, wherein said method
30 further reduces the risk of a fatal outcome for said subject.
7. The method according to any one of the preceding claims, wherein said method further reduces the risk of said subject recovering with sequelae.
- 35 8. The method according to any one of the preceding claims, wherein said method comprises at least 16 months of chronic administration of liraglutide.

9. The method according to any one of the preceding claims, wherein liraglutide is administered once daily.
- 5 10. The method according to any one of the preceding claims, wherein liraglutide is administered once daily in an amount in the range of 0.4-4.0 mg per day, such as 0.6, 1.2, or 1.8 mg per day.
- 10 11. The method according to any one of the preceding claims, wherein liraglutide is administered in the form of a pharmaceutical composition comprising about 1-20 mg/ml liraglutide, about 2-15 mM phosphate buffer, about 2-25 mg/ml propylene glycol, about 1-18 mg/ml phenol, and has a pH in the range of 7.5-9.0.
- 15 12. The method according to any one of the preceding claims, wherein liraglutide is administered in the form of a pharmaceutical composition comprising about 6 mg/ml liraglutide, about 1.42 mg/ml disodium phosphate dihydrate, about 14.0 mg/ml propylene glycol, about 5.5 mg/ml phenol, and has pH of about 8.15.
- 20 13. The method according to any one of the preceding claims, wherein liraglutide is administered in the form of a pharmaceutical composition comprising 6 mg/ml liraglutide, 1.42 mg/ml disodium phosphate dihydrate, 14.0 mg/ml propylene glycol, 5.5 mg/ml phenol, and has pH of 8.15.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/054986

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K38/26 A61P3/10 A61P17/02 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHARALAMPOS TZANETAKOS ET AL: "Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece", BMC HEALTH SERVICES RESEARCH, BIOMED CENTRAL, LONDON, GB, vol. 14, no. 1, 22 September 2014 (2014-09-22), page 419, XP021197159, ISSN: 1472-6963, DOI: 10.1186/1472-6963-14-419	1-10
Y	abstract; Tables 1, 4 -----	11-13
Y	WO 2015/169789 A1 (NOVO NORDISK AS [DK]) 12 November 2015 (2015-11-12) p. 28, l. 10-13 ----- -/--	11-13
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 26 April 2017		Date of mailing of the international search report 08/05/2017
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Scheithe, Rupert

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/054986

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	IEPSEN EVA WINNING ET AL: "Liraglutide for Type 2 diabetes and obesity: a 2015 update", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, EXPERT REVIEWS LTD, GB, vol. 13, no. 7, 1 January 2015 (2015-01-01), pages 753-767, XP008182288, ISSN: 1744-8344 the whole document -----	1-13
A	RAFFAELE MARFELLA ET AL: "Dipeptidyl Peptidase 4 Inhibition May Facilitate Healing of Chronic Foot Ulcers in Patients with Type 2 Diabetes", EXPERIMENTAL DIABETES RESEARCH, vol. 66, no. 4, 1 January 2012 (2012-01-01), pages S7-11, XP055076736, ISSN: 1687-5214, DOI: 10.1016/j.regpep.2004.04.014 whole document, particularly abstract, p. 9, second half of right column -----	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2017/054986

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015169789 A1	12-11-2015	EP 3139948 A1	15-03-2017
		TW 201625289 A	16-07-2016
		US 2017043014 A1	16-02-2017
		WO 2015169789 A1	12-11-2015
